Literature DB >> 7923149

Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis.

M Satoh1, M G Cherian, N Imura, H Shimizu.   

Abstract

The expression of metallothionein (MT) in certain tumor cells has been associated with resistance to anticancer drugs. In the present study, we examined the effects of inhibition of MT synthesis on resistance to anticancer drugs of human bladder tumor which were inoculated in nude mice. The results show that pretreatment of tumor-bearing mice with zinc salts increased MT content, both in normal and tumor tissues, with a marked reduction in the antitumor activity of cisplatin, Adriamycin, and melphalan. Injection of propargylglycine, an inhibitor of cystathionase, decreased MT induction by zinc in the tumor and diminished the resistance to these drugs. These results suggest a role for MT in drug resistance in tumors, and injection of propargylglycine may provide a potential means to overcome drug resistance caused by elevation of MT levels in certain tumors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923149

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  Mammalian metallothionein in toxicology, cancer, and cancer chemotherapy.

Authors:  Mohammad Namdarghanbari; William Wobig; Susan Krezoski; Niloofar M Tabatabai; David H Petering
Journal:  J Biol Inorg Chem       Date:  2011-08-07       Impact factor: 3.358

2.  Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis.

Authors:  Matthieu Peyre; Frédéric Commo; Carmela Dantas-Barbosa; Felipe Andreiuolo; Stéphanie Puget; Ludovic Lacroix; Françoise Drusch; Véronique Scott; Pascale Varlet; Audrey Mauguen; Philippe Dessen; Vladimir Lazar; Gilles Vassal; Jacques Grill
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

3.  Differential expression of metallothionein 1 and 2 isoforms in breast cancer lines with different invasive potential: identification of a novel nonsilent metallothionein-1H mutant variant.

Authors:  Siew-Kian Tai; Owen June-Keong Tan; Vincent Tak-Kwong Chow; Rongxian Jin; J Louise Jones; Puay-Hoon Tan; Anita Jayasurya; Boon-Huat Bay
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

Review 4.  [Perspectives for molecular diagnostics exemplified by urothelial bladder carcinoma].

Authors:  M-O Grimm; M Burchardt; W A Schulz
Journal:  Urologe A       Date:  2003-04-08       Impact factor: 0.639

5.  Functional analysis of the transcription repressor PLU-1/JARID1B.

Authors:  Angelo G Scibetta; Samantha Santangelo; Julia Coleman; Debbie Hall; Tracy Chaplin; John Copier; Steve Catchpole; Joy Burchell; Joyce Taylor-Papadimitriou
Journal:  Mol Cell Biol       Date:  2007-08-20       Impact factor: 4.272

6.  BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line.

Authors:  Manny D Bacolod; Randy Fehdrau; Stewart P Johnson; Nancy S Bullock; Darell D Bigner; Michael Colvin; Henry S Friedman
Journal:  Cancer Chemother Pharmacol       Date:  2008-07-17       Impact factor: 3.333

7.  The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cells.

Authors:  Anne M Galea; Vincent Murray
Journal:  Cancer Inform       Date:  2008-06-10

Review 8.  Cellular mechanisms of zinc dysregulation: a perspective on zinc homeostasis as an etiological factor in the development and progression of breast cancer.

Authors:  Samina Alam; Shannon L Kelleher
Journal:  Nutrients       Date:  2012-07-30       Impact factor: 5.717

Review 9.  The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment.

Authors:  Yanghong Ni; Xiaoting Zhou; Jia Yang; Houhui Shi; Hongyi Li; Xia Zhao; Xuelei Ma
Journal:  Front Cell Dev Biol       Date:  2021-05-20

10.  Microarray-assisted pathway analysis identifies MT1X & NFκB as mediators of TCRP1-associated resistance to cisplatin in oral squamous cell carcinoma.

Authors:  Bo Peng; Yixue Gu; Yan Xiong; Guopei Zheng; Zhimin He
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.